Sign in

    Mazahir Alimohamed

    Biotech Equity Research Analyst at Leerink Partners

    Mazahir Alimohamed, M.D., MPH, is a Biotech Equity Research Analyst at Leerink Partners, specializing in coverage of innovative therapeutic and biotechnology companies, including Xencor, Inc. and Zai Lab Ltd, with a focus on genetic medicine and rare diseases. He has delivered investment research and ratings—such as ‘Outperform’ on key stocks—with a demonstrated track record of providing both thematic and fundamental analysis. Mazahir joined Leerink Partners in 2023 following prior experience in healthcare and investment banking, leveraging clinical expertise in his research approach. He holds an M.D., an M.P.H., and is registered with FINRA (CRD# 7971901), meeting all securities regulatory requirements for equity analysts.

    Mazahir Alimohamed's questions to Aquestive Therapeutics (AQST) leadership

    Mazahir Alimohamed's questions to Aquestive Therapeutics (AQST) leadership • Q2 2025

    Question

    Mazahir Alimohamed of Leerink Partners inquired about the likelihood of an FDA Advisory Committee (AdCom) meeting for Anafilm and the company's confidence in its clinical data package.

    Answer

    CEO Daniel Barber stated that Aquestive expects clarity on a potential AdCom in the coming weeks following the FDA's mid-cycle review and that the company is prepared. Chief Medical Officer Dr. Carl Kraus affirmed confidence in the robust clinical package, highlighting it as one of the largest epinephrine studies conducted, with 10 independent studies and over 930 exposures.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Akebia Therapeutics (AKBA) leadership

    Mazahir Alimohamed's questions to Akebia Therapeutics (AKBA) leadership • Q2 2025

    Question

    Mazahir Alimohamed from Leerink Partners questioned the outlook for Auryxia's competitive dynamics for the remainder of 2025, given its year-over-year revenue growth despite an authorized generic on the market. He also asked how Akebia is positioning for potential future generic entrants.

    Answer

    SVP & CCO Nicholas Grund attributed Auryxia's strong performance to physician familiarity and significantly improved market access. CEO John Butler noted that while they have visibility on the current authorized generic, they remain cautious about future competition. CFO Erik Ostrowski added that the company budgets conservatively for Auryxia, and any delay in further generic entry represents upside to their financial plan.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to LEXICON PHARMACEUTICALS (LXRX) leadership

    Mazahir Alimohamed's questions to LEXICON PHARMACEUTICALS (LXRX) leadership • Q2 2025

    Question

    Mazahir Alimohamed from Leerink Partners questioned how Vertex's recent trial failure in pain impacts Lexicon's confidence and asked if the baseline echo required in the sotagliflozin HCM trial would be a commercial requirement.

    Answer

    CEO Mike Exton asserted that Vertex's results actually increase confidence in pilavapitan, as it validates their novel mechanism of action which has shown consistent efficacy, unlike the mixed results for NaV inhibitors in neuropathic pain. SVP & CMO Dr. Craig Granowitz explained that a baseline echo is standard of care for heart failure patients and is not expected to be a commercial barrier, distinguishing it from the frequent monitoring and REMS programs required for CMIs.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Lantheus Holdings (LNTH) leadership

    Mazahir Alimohamed's questions to Lantheus Holdings (LNTH) leadership • Q2 2025

    Question

    Mazahir Alimohamed of Leerink Partners requested details on the commercial opportunity for tau imaging agent MK6240 and its strategic fit within the company's broader Alzheimer's franchise alongside NeuroSeq.

    Answer

    CEO Brian Markison described tau imaging's value as "unmistakable" for future patient selection and monitoring in clinical trials, with the potential for the neuro portfolio to be similar in size to Polarify. President Paul Blanchfield added that the acquired LMI team provides a strong commercial platform to launch MK6240 and lead the neuro PET diagnostic market.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to AMARIN CORP PLC\UK (AMRN) leadership

    Mazahir Alimohamed's questions to AMARIN CORP PLC\UK (AMRN) leadership • Q2 2025

    Question

    Mazahir Alimohamed, on behalf of Roana Ruiz at Leerink Partners, questioned the realistic expectations for European market penetration over the next three to five years under the Recordati partnership and how Recordati's broader reach into primary care differentiates its approach from Amarin's previous specialty-focused strategy.

    Answer

    CEO Aaron Berg explained that it is too early to provide long-term forecasts for Europe but expressed optimism for accelerated growth. He highlighted the key strategic difference: Amarin's direct approach was limited and focused on specialists, whereas Recordati has a well-established infrastructure in both specialty cardiology and primary care. This broader reach is expected to enable a greater commercial impact and wider patient access than Amarin could have achieved alone.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Xeris Biopharma Holdings (XERS) leadership

    Mazahir Alimohamed's questions to Xeris Biopharma Holdings (XERS) leadership • Q1 2025

    Question

    Eason Lee, on behalf of Mazahir Alimohamed, inquired about the primary drivers of the company's operational efficiency and its sustainability, and also asked for details on the development milestones and strategy for the pipeline product XP-8121.

    Answer

    CFO Steven Pieper attributed operational efficiency to strong top-line growth, improving gross margins, and disciplined expense management, confirming the company expects to remain adjusted EBITDA positive. CEO John Shannon added that a comprehensive update on XP-8121's development pathway, regulatory strategy, and timelines will be provided at the Analyst and Investor Day on June 3.

    Ask Fintool Equity Research AI

    Mazahir Alimohamed's questions to Xeris Biopharma Holdings (XERS) leadership • Q4 2024

    Question

    Mazahir Alimohamed, on for Roanna Ruiz, asked about potential plans to further expand the Recorlev sales force in 2025 and inquired about the commercial synergies between the existing product portfolio and the future launch of XP-8121.

    Answer

    CFO Steven Pieper stated that while the company will remain opportunistic, there are no firm plans for another Recorlev sales force expansion in 2025. CEO John Shannon described XP-8121 as a "perfect fit" for the company's commercial infrastructure, highlighting its ability to leverage the existing endocrinology footprint, patient support services, and proven XeriSol technology platform.

    Ask Fintool Equity Research AI